Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Charlottesville, Virginia Clinical Trials

A listing of Charlottesville, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (28) clinical trials

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

PRIMARY OBJECTIVES: I. To perform a phase I dose-escalation study in patients with recurrent or refractory neuroblastoma (NB) and other GD2-positive tumors to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) for anti-CD3 x hu3F8 bispecific antibody (GD2Bi)-armed activated T cells (aATC) infused twice a ...

Phase

5.55 miles

Learn More »

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes ...

Phase

5.55 miles

Learn More »

Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound

This study requires a screening day and two visits on separate days to the Clinical Research Unit (CRU). Three visits total. Screening Visit: The subjects will undergo detailed history and physical examination. The inclusion and exclusion criteria will be reviewed. The details of the study procedures, potential risks and benefits ...

Phase

5.55 miles

Learn More »

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

Once subjects are determined eligible, white blood cells (lymphocytes) are collected via leukapheresis procedure. Depending on arm/schedule, about 4-5 weeks later, study treatment will begin. For HER2 BATs, the white blood cells, specifically T cells, are then mixed with two proteins - OKT3 and IL-2 -- which activates the cells ...

Phase

5.55 miles

Learn More »

Randomized Clinical Trial of MRI for Optimal CRT Outcomes

At baseline, patients will have CMR, echocardiography, and cardiopulmonary exercise testing. In patients randomized to CMR guidance for the CRT procedure, LV lead placement will be guided by the MRI information related to scar, activation and anatomy. Patients will have follow-up assessments at 6 and 12 months.

Phase

5.55 miles

Learn More »

Ruxolitinib Phosphate Paclitaxel and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. Determine whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy is safe and tolerable in the primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (Phase I) II. Demonstrate whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy results ...

Phase

5.55 miles

Learn More »

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

This study evaluates whether it is safe to administer a helper peptide vaccine with dabrafenib and trametinib. This study will also evaluate the effects of the combination of the peptide vaccine and dabrafenib and trametinib on the immune system. We will monitor these effects by performing tests in the laboratory ...

Phase

5.55 miles

Learn More »

Preoperative Bexarotene Treatment for Cushing's Disease

Cushing's disease refers to a condition of glucocorticoid excess caused by an adrenocorticotropic hormone (ACTH) producing pituitary tumor, which account for 10-15% of all pituitary tumors. The majority of corticotroph tumors are microadenomas at the time of diagnosis, and accurate surgical and histologic identification of these tumors can be challenging. ...

Phase

5.55 miles

Learn More »

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Dose Escalation Stage: to determine the schedule and maximum tolerated dose (MTD) and/or recommended Expansion Stage dose of cabozantinib when taken in combination with a standard dosing regimen of atezolizumab (1200 mg infusion, once every 3 weeks). Expansion Stage: to determine the preliminary efficacy (objective response rate [ORR] per RECIST ...

Phase

5.55 miles

Learn More »

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Phase

5.55 miles

Learn More »